arrow
L

Lucjan Wyrwicz

maria sklodowska-curie national cancer research institute
H指数:50
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)

一线替雷利珠单抗联合化疗对比安慰剂联合化疗在不可切除的局部晚期/转移性食管鳞状细胞癌中的应用:一项随机III期试验(RATIONALE-306)3年生存随访的最低数据

2026-09-030
OAAI
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析

2025-03-010
OAAI
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析

2025-03-010
OAAI
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

KEYNOTE-811研究的III期最终总生存数据,该研究评估了帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性、不可切除或转移性胃/胃食管结合部腺癌。

2024-12-010
PRE
Neoadjuvant and adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study

新辅助和辅助帕博利珠单抗(pembro)联合化疗(chemo)治疗局部晚期胃或胃食管结合部(G/GEJ)癌:KEYNOTE-585 III期研究的患者报告结局(PROs)

2024-09-010
PRE
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up

替雷利珠单抗(TIS)联合化疗(CT)对比安慰剂(PBO)联合化疗(CT)治疗HER2阴性晚期或转移性胃或胃食管结合部腺癌(GC/GEJC):RATIONALE-305研究至少3年生存随访

2024-09-014
PRE
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

阳光的通俗易懂的总结: 三氟尿苷/替匹拉西和贝伐单抗治疗难治性转移性结直肠癌

2024-07-020
OAAI
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab加化疗与安慰剂加化疗作为晚期胃或胃食管交界处腺癌的一线治疗: 原理305的随机,双盲,3期试验

2024-05-2810
OA
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
2024-04-013
OAAI
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

Rivoceranib,一种VEGFR-2抑制剂,单药治疗先前治疗的晚期或转移性胃或胃食管交界处癌患者 (ANGEL研究): 一项国际,随机,安慰剂对照,3期试验

2024-01-281
OAAI
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Pembrolizumab联合曲妥珠单抗和化疗治疗HER2-positive胃或胃食管交界处腺癌: 来自3期KEYNOTE-811随机安慰剂对照试验的中期分析

LANCET
IF88.5
2023-12-01120
PRE
A Prospective Study on the Roles of the Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR) in Patients with Locally Advanced Rectal Cancer

淋巴细胞与单核细胞比率 (LMR),中性粒细胞与淋巴细胞比率 (NLR) 和血小板与淋巴细胞比率 (PLR) 在局部晚期直肠癌患者中的作用的前瞻性研究

2023-11-148
OAAI
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

durvalumab联合5-氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛 (FLOT) 治疗可切除胃癌和胃食管交界癌 (GC/GEJC) 的病理完全缓解 (pCR): 全球III期马特洪峰研究的中期结果

2023-11-016
PRE